Romera, Alvaro <br/><br/>
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.  [electronic resource] 

 -  The lancet. Gastroenterology & hepatology  12 2018 
 - 845-855 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2468-1253 
<br/><br/><label>Standard No.: </label>10.1016/S2468-1253(18)30269-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies--blood<br/>Antineoplastic Agents, Immunological--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Area Under Curve<br/>Bevacizumab--adverse effects<br/>Biosimilar Pharmaceuticals--adverse effects<br/>Camptothecin--analogs & derivatives<br/>Colorectal Neoplasms--drug therapy<br/>Female<br/>Fluorouracil--therapeutic use<br/>Humans<br/>Intention to Treat Analysis<br/>Leucovorin--therapeutic use<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Organoplatinum Compounds--therapeutic use<br/>Progression-Free Survival<br/>Therapeutic Equivalency